Catalent Cell and Gene Content

  1. Manufacturing Strategies To Industrialize Autologous Therapies 9/30/2025

    Discover how a systematic approach to autologous cell therapy manufacturing can reduce costs, improve reliability, and accelerate access to life-changing treatments.

  2. Advanced iPSC Workflows: Accelerating Cell Therapy Development 9/30/2025

    Beyond offering our GMP-compliant iPS cells, we develop superior workflows for gene editing and differentiation to provide competitive platforms to our partners and accelerate their therapeutic programs.

  3. Streamline AAV-Based Gene Therapies With Off-The-Shelf Plasmids 8/14/2025

    Standardized, well-characterized plasmids and streamlined platform processes can significantly accelerate viral vector development, improve consistency, and support scalable, high-quality gene therapy manufacturing.

  4. UpTempo℠: Seamless Transitions From Bench To CGT Applications 6/19/2025

    Accelerate cell and gene therapy development with high-yield, regulatory-compliant plasmid DNA manufacturing that shortens timelines, minimizes risks, and streamlines your supply chain.

  5. 07.14.23 -- Accelerate Development Timelines With Improved Characterization Methods 7/14/2023

    07/14/23 Outsourced Pharma Newsletter

  6. UpTempo℠ AAV Platform Process

    Catalent’s UpTempo℠ AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18-20-month development timeline for drug product in half.

  7. From Platform To Patient: Streamlining Gene Therapy Development

    Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

  8. Exploring An Integrated Solution For AAV Vector Clinical Production

    Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.

  9. Accelerating Your Gene Therapy: Not All Platforms Are Created Equal

    Standardized methods, materials, and analytics are critical for overcoming hurdles in the gene therapy space. Explore how a platform approach to fast-track AAVs can enhance quality and efficiency.